Neurol. praxi. 2009;10(6):369-371

Prophylactic treatment of migraine

MUDr.Ingrid Niedermayerová
Neurologická ambulance Quattromedica Brno a II. neurologická klinika LF MU a FN Brno

Prophylactic drug treatment is foregrounded in attempt to reduce frequency, duration or severity of migraine attacks, further after inefficiency

or contraindications of acute therapy. Drugs of the first choice are initially administrated, i. e. valproate, topiramate, metoprolol,

flunarizine. If these drugs are not effective, are contraindicated or in case of comorbidity, we use drugs of the second choice (amitriptylin)

or another prophylactic drugs. Monotherapy is preferred at first, prophylactic drugs may be combined. Duration of prophylaxis is usually

6–9–12 months. During menstrual migraine, nonsteroidal anti-inflammatory drugs (naproxen) or triptans (frovatriptan, naratriptan) are

administrated intermittently, another option is hormonal prophylaxis. Using of magnesium is without risk during pregnancy. In resistant

cases metoprolol can be applied. The failure of prophylaxis can be caused by the wrong diagnosis of the headache.

Keywords: migraine, prophylaxis, topiramate, valproate, betablockers, amitriptylin

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Niedermayerová I. Prophylactic treatment of migraine. Neurol. praxi. 2009;10(6):369-371.
Download citation

References

  1. Češková E. Duálně působící antidepresiva. Remedia 2006; 16: 594-597.
  2. Dočekal P, Keller O, Marková J, Opavský J. Bolesti hlavy. In Rokyta R, Kršiak M, Kozák J (Eds). Bolest. Praha: Tigis 2006: 461-476.
  3. Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. European Journal of Neurology 2006; 13: 560-572. Go to original source... Go to PubMed...
  4. Headache Classification Subcommittaee of the International Headache Society. The International Classification and Diagnostic Criteria of Headache Disorders. 2nd Edition, Cephalgia 2004; 24(1): 160.
  5. Marková J, Procházková M, Doležal T. Frovatriptan. Farmakoterapie. 2006; 3: 265-270.
  6. Mastík J. Léčba menstruační a perimenstruační migrény. Neurol. pro praxi. 2008; (9)6: 356-360.
  7. Niedermayerová I, Mastík J. Lisinopril je účinný v profylaxi migrény. Practicus. 2007; 5-6: 200-203.
  8. Opavský J, Doležil D, Mastík J, Marková J, Grünermelová M, Niedermayerová I, Rejda J, Dočekal P, Opavská H. Comparison between migraine treatment by headache specialists and primary care physicians in the Czech republic. Cephalalgia. 2007; 27: 652-653.
  9. Peatfield P, Dodick DW. Headaches. Fine Print, Oxford, 2002: 625.
  10. Silberstein SD, Diener HC. Clinician´s Manual on Migraine. Current Medicine Group. London, 2006: 58s.
  11. Waberžinek G. Bolesti hlavy. Triton, Praha, 2000: 191.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.